We are live on
!
Find out more
Adage Capital Partners Portfolio holdings
AUM
$64.8B
1-Year Est. Return
42.7%
This Fund
S&P 500
This Quarter
Est. Return
+5.26%
1 Year Est. Return
+42.7%
3 Year Est. Return
+139.29%
5 Year Est. Return
+204.38%
10 Year Est. Return
+879.75%
AUM
$57.2B
AUM Growth
+$551M
(+0.97%)
Cap. Flow
-$331M
Cap. Flow
% of AUM
-0.58%
Top 10 Holdings %
Top 10 Hldgs %
31.76%
Holding
1,006
New
143
Increased
295
Reduced
385
Closed
137
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
ConocoPhillips
COP
|
+$247M |
| 2 |
Bristol-Myers Squibb
BMY
|
+$183M |
| 3 |
WCC
WESCO International
WCC
|
+$178M |
| 4 |
Gilead Sciences
GILD
|
+$154M |
| 5 |
Delta Air Lines
DAL
|
+$145M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
MRO
Marathon Oil Corporation
MRO
|
+$221M |
| 2 |
3M
MMM
|
+$157M |
| 3 |
MRSH
Marsh
MRSH
|
+$120M |
| 4 |
Johnson & Johnson
JNJ
|
+$106M |
| 5 |
Regeneron Pharmaceuticals
REGN
|
+$105M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 29.09% |
| 2 | Healthcare | 13.87% |
| 3 | Financials | 11.48% |
| 4 | Consumer Discretionary | 10.65% |
| 5 | Industrials | 8.65% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
676
Astera Labs
ALAB
$54.6B
| $6.81M | 0.01% |
51,432
-608,923
| -92% | -$57.1M |
|
677
Pultegroup
PHM
$25.3B
| $6.71M | 0.01% |
61,600
+11,000
| +22% | +$1.43M |
|
678
Caesars Entertainment
CZR
$6.13B
| $6.63M | 0.01% |
198,500
-5,400
| -3% | -$214K |
|
679
Arcus Biosciences
RCUS
$3.48B
| $6.6M | 0.01% |
+443,000
| New | +$7.23M |
|
680
Epsilon Energy
EPSN
$165M
| $6.59M | 0.01% |
1,061,909
| – | – |
|
681
Travere Therapeutics
TVTX
$5.92B
| $6.56M | 0.01% |
376,800
-23,200
| -6% | -$410K |
|
682
BrightSpring Health Services
BTSG
$12.5B
| $6.53M | 0.01% |
383,377
-581,153
| -60% | -$10M |
|
683
Savara
SVRA
$1.13B
| $6.5M | 0.01% |
2,115,771
-4,637,930
| -69% | -$16.2M |
|
684
Brown-Forman Class B
BF.B
$13B
| $6.46M | 0.01% |
170,132
-2,700
| -2% | -$119K |
|
685
Viatris
VTRS
$20.6B
| $6.43M | 0.01% |
+516,364
| New | +$6.35M |
|
686
Edgewise Therapeutics
EWTX
$4.84B
| $6.41M | 0.01% |
240,000
+218,491
| +1,016% | +$6.96M |
|
|
ATXS
687
DELISTED
Astria Therapeutics
ATXS
| $6.38M | 0.01% |
713,200
-54,743
| -7% | -$581K |
|
|
INGM
688
Ingram Micro Holding
INGM
$6.63B
| $6.3M | 0.01% |
+325,000
| New | +$7.29M |
|
689
Nabors Industries
NBR
$1.16B
| $6.29M | 0.01% |
110,000
-15,000
| -12% | -$1.07M |
|
690
Corbus Pharmaceuticals
CRBP
$177M
| $6.24M | 0.01% |
528,937
| – | – |
|
691
Equity Residential
EQR
$25.4B
| $6.23M | 0.01% |
+86,882
| New | +$6.38M |
|
692
Mirum Pharmaceuticals
MIRM
$6.45B
| $6.2M | 0.01% |
150,000
+70,000
| +88% | +$2.92M |
|
693
Madrigal Pharmaceuticals
MDGL
$11.9B
| $6.16M | 0.01% |
+19,960
| New | +$5.61M |
|
694
NovoCure
NVCR
$1.87B
| $5.96M | 0.01% |
+200,000
| New | +$4.23M |
|
695
Equitable Holdings
EQH
$14B
| $5.9M | 0.01% |
125,000
+25,000
| +25% | +$1.15M |
|
696
Ivanhoe Electric
IE
$1.69B
| $5.84M | 0.01% |
772,890
-123,088
| -14% | -$1.14M |
|
697
Mohawk Industries
MHK
$9.19B
| $5.83M | 0.01% |
48,970
+29,600
| +153% | +$4.14M |
|
698
Relay Therapeutics
RLAY
$4.29B
| $5.77M | 0.01% |
1,400,000
-250,000
| -15% | -$1.36M |
|
699
Camden Property Trust
CPT
$11.1B
| $5.77M | 0.01% |
49,700
-13,300
| -21% | -$1.59M |
|
|
CLDT
700
Chatham Lodging
CLDT
$623M
| $5.74M | 0.01% |
+641,087
| New | +$5.68M |
|
Similar funds
Adage Capital Partners's Q4 2024 Portfolio in Review
As of Q4 2024, Adage Capital Partners held 1,006 positions worth $57.2B, up 0.97% from $56.6B the previous quarter. Its ten largest holdings account for 32% of the portfolio.
Adage Capital Partners's Q4 2024 filing shows 143 new, 295 increased, 385 reduced and 137 closed positions. Its largest new stake was Gilead Sciences: 1,714,130 shares worth $158M. The largest sale was Marathon Oil Corporation, an estimated $221M.
By sector, the portfolio is most concentrated in Technology at 29% of assets, up from 28% a quarter earlier, followed by Healthcare and Financials.
- Adage Capital Partners's largest Q4 2024 buy was Gilead Sciences: 1,714,130 shares worth $158M.
- Adage Capital Partners added most to ConocoPhillips in Q4 2024, an estimated $247M increase.
- Adage Capital Partners's biggest Q4 2024 reduction was 3M, cutting an estimated $157M.
- Adage Capital Partners fully exited Marathon Oil Corporation in Q4 2024, selling an estimated $221M.
- Adage Capital Partners's ten largest holdings make up 32% of its $57.2B portfolio in Q4 2024.
- Adage Capital Partners opened 143 new positions and closed 137 in Q4 2024.
- Adage Capital Partners's portfolio value rose 0.97% quarter-over-quarter to $57.2B.
Based on Adage Capital Partners's 13F filing for Q4 2024, filed 14 Feb 2025.